Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group. Charpentier C, et al. Among authors: taburet am. PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621. Epub 2013 Jan 17. PLoS One. 2013. PMID: 23349724 Free PMC article. Clinical Trial.
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group. Goujard C, et al. Among authors: taburet am. Clin Pharmacokinet. 2005;44(12):1267-78. doi: 10.2165/00003088-200544120-00005. Clin Pharmacokinet. 2005. PMID: 16372824 Clinical Trial.
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM; Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group. Piketty C, et al. Among authors: taburet am. Antivir Ther. 2006;11(2):213-21. Antivir Ther. 2006. PMID: 16640102 Clinical Trial.
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
Barrail-Tran A, Morand-Joubert L, Poizat G, Raguin G, Le Tiec C, Clavel F, Dam E, Chêne G, Girard PM, Taburet AM; Puzzle-1 (ANRS 104) Study Group. Barrail-Tran A, et al. Among authors: taburet am. Antimicrob Agents Chemother. 2008 May;52(5):1642-6. doi: 10.1128/AAC.01314-07. Epub 2008 Feb 19. Antimicrob Agents Chemother. 2008. PMID: 18285478 Free PMC article. Clinical Trial.
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.
Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Duval X, et al. Among authors: taburet am. Fundam Clin Pharmacol. 2009 Aug;23(4):491-500. doi: 10.1111/j.1472-8206.2009.00693.x. Fundam Clin Pharmacol. 2009. PMID: 19709326 Free PMC article. Clinical Trial.
192 results